Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism MDM2-p53 interaction inhibitor(p53-binding protein Mdm-2 p53 interaction inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC25H27Cl2N3O4 |
InChIKeyOTUBDDRFPQLPKD-QFIPXVFZSA-N |
CAS Registry2098347-07-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Preclinical | US | 17 Jan 2014 |